Micell's technology is designed to enable stable, controlled-release delivery of 'limus drugs (e.g. sirolimus, also known as rapamycin) and provides targeted pharmacokinetic profiles to optimize local dosing and healing.

Micell's platform technology enables a portfolio of proprietary and advanced devices for multiple indications. In summary, Micell's technology platform has been designed to make clinically meaningful improvements in patient outcomes:

KEY FEATURE		TARGETED POTENTIAL CLINICAL BENEFIT
Composition controlled and completely absorbed for local therapy		More consistent tissue response No liability of long-term polymer or residual drug
Linear pharmacokinetic profile of the drug concurrent with the absorption of a bioabsorbable polymer		Optimize healing and safety
Drug is maintained in a crystalline morphology; enabled by Micell's novel process and formulation technology		Ensure stability and sustained potency of the drug both on the shelf and in vivo